; HPV Testing and Pap Test Market Size, Share and Report Forecasts to 2032

HPV Testing and Pap Test Market

HPV Testing and Pap Test Market: By Product Type (HPV test, Pap test and Co-test); By Application (Cervical cancer and Vaginal cancer); By Distribution Channel (Hospitals and clinics, Diagnostic centers and Others), And Region - Global Analysis of Market Size, Share & Trends For 2021-2022 And Forecasts To 2032

Published on: May-2023
Report Code: FG HC 01539
No. of Pages: 170-350
Report Format: PDF

Product Overview

HPV Testing and Pap Test Market is expected to surpass USD 9.10 billion by 2032 from USD 2.99 billion in 2021 at a CAGR of 7.4% in the coming years, i.e., 2022-32.

The most prevalent sexually transmitted infection in the world is caused by the papillomaviridae family's Human Papillomavirus (HPV). HPV is divided into two categories, such as low-risk HPVs and high-risk HPVs, depending on the risk involved. Cervical and vaginal cancers are now well known to be caused by high-risk strains of the HPV virus. A double-stranded DNA tumour virus called the human papillomavirus promotes the growth of epithelial cells on the cutaneous and mucosal surfaces.

Market Highlights

The HPV Testing and Pap Test Market is expected to project a notable CAGR of 7.4% in 2032.

HPV Testing and Pap Test Market is expected to surpass USD 9.10 billion by 2032 from USD 2.99 billion in 2021 at a CAGR of 7.4% in the coming years, i.e., 2022-32. Rising demand for technologically sophisticated diagnostic procedures for screening cervical and vaginal cancers is one of the main factors anticipated to propel the market for human papillomavirus testing and Pap tests over the forecast period. The market for Pap tests and human papillomavirus testing is anticipated to be driven by a number of technological developments, such as the creation of human papillomavirus type 16 and the use of various molecular markers in screening techniques.

Market Analysis of HPV Testing and Pap Test Market

HPV Testing and Pap Test Market: Segments

The pap test segment is expected to grow with a higher CAGR during 2022-32

HPV Testing and Pap Test Market is categorized on the basis of Product Type into HPV test, Pap test and Co-test. Due to its extensive adoption in screening programs, the Pap test segment led the market for HPV testing and Pap tests in 2021. Further measures to raise public knowledge about Pap tests are anticipated to fuel the segment's expansion. Initial screening using HPV tests aids in finding abnormal cells that could develop into cancer. This aids in the early detection of disease and enables medical professionals to choose from a variety of preventive and/or therapeutic measures. As a result, it is projected that the HPV testing market would expand over the forecast period.

The hospital segment is expected to grow with a higher CAGR during 2022-32

HPV Testing and Pap Test Market is categorized on the basis of distribution channel into Hospitals and clinics, Diagnostic centers and Others. With an increase in patient load, pap test and HPV testing procedures will become more common in hospitals. Healthcare spending is rising as a result of an increased availability of cutting-edge equipment, the presence of skilled personnel, and a booming demand for relatively inexpensive diagnostic procedures. The availability of well-equipped assays and test kits for the detection of cervical and vaginal cancer in both public and private institutions, as well as the influx of numerous sophisticated technologies, will encourage the market's expansion.

Market Analysis of Global HPV Testing and Pap Test

Market Dynamics

Growth Drivers

Development of new screening test kits and increasing cases of cervical cancer

Due to a significant group of health-conscious consumers, the pharmaceutical business is growing and developing new screening test kits, which opens up the market for Pap and HPV tests. Additionally, the prevalence of cervical cancer cases is rising across several regions, which increases demand for screening tests for the human papillomavirus and propels market expansion. A few other HPV testing and Pap test market trends that propel market expansion include the rise in the introduction of various screening test kits and the rise in new HPV type testing kits for cervical cancer screening by various major players throughout the world.

Need for technological improvements and awareness campaigns is expected to surge demand

One of the most prevalent malignancies in women over 40 is cervical cancer. According to estimates, HPV infections cause 99% or more of occurrences of cervical cancer. One of the key factors anticipated to propel the market for HPV testing and Pap tests over the forecast period is the rising need for technologically sophisticated diagnostic treatments for screening cervical and vaginal malignancies. The market for Pap tests and HPV testing is anticipated to grow as a result of numerous technological improvements and the use of numerous molecular markers in screening methods. Furthermore, one of the key factors anticipated to propel the market for Pap tests and HPV testing during the forecast period is the growing number of awareness campaigns by various organizations for cervical cancer screening.

Restraint

Modifications to regulatory standards and high pricing is likely to hamper the Market Growth

The development of the HPV testing and Pap test markets is impeded by modifications to regulatory standards for cervical cancer screening. Additionally, the global accessibility of the human papillomavirus vaccine could impede market expansion. Furthermore, high cost of testing is also likely to hamper the market for HPV testing and Pap testing in the forecasted period.

Recent Developments

  • The World Health Organization (WHO) estimates that more than 500,000 women will get cervical cancer in 2020, and 342,000 will pass away as a result. In accordance with the World Health Assembly's endorsement of WHO's global strategy for eradicating cervical cancer in 2020, 70% of women worldwide must undergo routine high-performance cervical cancer screenings, and 90% of those who do so must receive the necessary treatment, which may include surgery.
  • According to predictions from the American Cancer Society, 14,110 new cases of invasive cervical cancer were found in the country in 2022. Thus, the rise in cervical cancer incidence globally may spur an increase in demand for PAP and HPV tests, propelling the market's expansion.

HPV Testing and Pap Test Market:

Key Players

  • Arbor vita corporation 

         (Company Overview, Business Strategy, Key Product Offerings, Financial Performance,      Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

  • Becton, Dickinson & Company
  • Qiagen NV
  • Diagcor Bioscience Incorporation Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Mylab Discovery Solutions Pvt. Ltd
  • Seegene Inc
  • Femasys Inc
  • Other Prominent Players

HPV Testing and Pap Test Market: Regions

HPV Testing and Pap Test Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America registered a sizable share of the HPV Testing and Pap Test Market in 2021. Rising demand for technologically sophisticated diagnostic procedures for screening cervical and vaginal cancers is one of the main factors anticipated to propel the market for human papillomavirus testing and Pap tests over the forecast period. The market for Pap tests and human papillomavirus testing is anticipated to be driven by a number of technological developments, such as the creation of human papillomavirus type 16 and the use of various molecular markers in screening techniques.

HPV Testing and Pap Test Market: Regions

Impact of Covid-19 on HPV Testing and Pap Test Market

Due to the demands placed on current laboratory services and the effectiveness of HPV-based screening in light of the rising SARS-CoV-2 admissions, the HPV testing and pap test sector saw sluggish growth in reaction to the COVID-19 pandemic. Cancer screening services were disrupted as a result of a staffing shortage and potential delays in main HPV testing breakthroughs, which adversely impacted the market's expansion during the outbreak.

HPV Testing and Pap Test Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
  • Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

HPV Testing and Pap Test Market report also contains analysis on:

HPV Testing and Pap Test Market Segments:

  • By Product Type
    • HPV test
    • Pap test
    • Co-test
  • By Application
    • Cervical cancer
    • Vaginal cancer
  • By Distribution Channel
    • Hospitals and clinics
    • Diagnostic centers
    • Others
    • HPV Testing and Pap Test Market Dynamics
    • HPV Testing and Pap Test Market Size
    • Supply & Demand
    • Current Trends/Issues/Challenges
    • Competition & Companies Involved in the Market
    • Value Chain of the Market

HPV Testing and Pap Test Market Report Scope and Segmentation

Report Attribute

Details

Market Size Value in 2021

USD 2.99 billion

Revenue Forecast in 2032

USD 9.10 billion

Growth Rate

CAGR of 7.4% from 2022 to 2032

Base Year for Estimation

2021

Quantitative Units

Revenue in USD billion and CAGR from 2022 to 2032

Report Coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments Covered

Product Type, Application, Distribution channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

Key Companies Profiled

Arbor vita corporation, Becton, Dickinson & Company, Qiagen NV, Diagcor Bioscience Incorporation Ltd., Enzo Biochem, Inc., F. Hoffmann-La Roche AG, Hologic, Inc., Mylab Discovery Solutions Pvt. Ltd, Seegene Inc and Other Prominent Players

Frequently Asked Questions (FAQ):

The HPV Testing and Pap Test Market size was estimated at USD 2.99 billion in 2021 and is expected to reach USD 9.10 billion in 2032

The most prevalent sexually transmitted infection in the world is caused by the papillomaviridae family's Human Papillomavirus (HPV). HPV is divided into two categories, such as low-risk HPVs and high-risk HPVs, depending on the risk involved. Cervical and vaginal cancers are now well known to be caused by high-risk strains of the HPV virus. A double-stranded DNA tumour virus called the human papillomavirus promotes the growth of epithelial cells on the cutaneous and mucosal surfaces.

he pap test and hospitals segments accounted for the larger share of the HPV Testing and Pap Test Market.

Key players in the HPV Testing and Pap Test Market are Arbor vita corporation, Becton, Dickinson & Company, Qiagen NV, Diagcor Bioscience Incorporation Ltd., Enzo Biochem, Inc., F. Hoffmann-La Roche AG, Hologic, Inc., Mylab Discovery Solutions Pvt. Ltd, Seegene Inc and Other Prominent Players.

Rising demand for technologically sophisticated diagnostic procedures for screening cervical and vaginal cancers is one of the main factors anticipated to propel the market for human papillomavirus testing and Pap tests over the forecast period.

Select License Type

$3199

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at info@fatposglobal.com with your request

Call us

Research Assistance

US : +1 (716) 218-3733
UK : +44 (208) 1235555



Select License Type

$3199

Report accessible by 1 user only

Sample Request

Client Testimonials

FATPOS CLIENT Appriciation DURING THE PROJECT

Clients